Ovarian Cancer

Ovarian cancer gives shikonin a different kind of relevance.

Here, the main story is less about direct tumour-cell killing and more about tumour-microenvironment signalling.

Why ovarian cancer is a logical target

Ovarian tumours often create a strongly immunosuppressive microenvironment.

One part of that depends on tumour-derived exosomes that carry signals into nearby immune cells.

Shikonin appears able to disrupt that communication channel.

Key evidence

In ovarian-cancer models, shikonin:

• reduced exosome formation and secretion

• blocked exosomal GAL3-mediated β-catenin activation

• reduced M2-polarised macrophage presence in tumour-microenvironment models

This is an unusual angle.

It targets a tumour-support loop rather than only the tumour cell itself.

Why this matters

M2 macrophages help protect tumours from immune attack.

They also support invasion, metastasis, and treatment resistance.

Reducing exosome-driven M2 polarisation gives shikonin a credible microenvironment mechanism in ovarian cancer.

Limits

• evidence is still preclinical

• immune-competent in vivo confirmation is limited

• no interaction data with PARP inhibitors or platinum-based standard care

• no subtype-specific evidence across serous, clear-cell, or endometrioid disease

Bottom line

Ovarian cancer is an early but mechanistically distinctive shikonin setting.

The exosome and macrophage story is more specific than generic antiproliferative claims.

It still needs much more validation before it can support clinical inference.

References

Frontiers in Pharmacology (2025). Review projecting shikonin as a therapeutic candidate in female reproductive cancers — exosome/GAL3/β-catenin and macrophage polarisation.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1627124/full